ClinicalTrials.gg
RecruitingNCT07431060Updated Feb 24, 2026

Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell Histiocytosis

An interventional study of Prednisone and Vincristine in Langerhans Cell Histiocytosis (LCH), sponsored by West China Second University Hospital. Recruiting at 11 sites in China. Open to participants aged 0 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-02-24.

Sponsored by West China Second University Hospital · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
0 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Histiocytosis, Langerhans-Cell with a site in China — 11 open to participants now, 13 under way, 1 of them phase 3. Histiocytosis, Langerhans-Cell · China.

Planned enrollment
2nd of 17
120 · median 40
Started
2026
with 3 others
No phase
2 of 17
2 open now
Primary completion
2030-12
later than 11 of 12 live
Registered
15th of 17
by date
Lead sponsor
3 of 17
West China Second University Hospital

Among the 17 studies in Histiocytosis, Langerhans-Cell with a site in China, this one is the 2nd largest by planned enrollment, is one of 4 that started in 2026, is one of 2 with no phase, reaches primary completion later than 11 of the 12 other live ones, and was the 15th registered.

Histiocytosis, Langerhans-Cell

81 studies on the registry are indexed under Histiocytosis, Langerhans-Cell; 23 are open to participants now.

Browse Histiocytosis, Langerhans-Cell studies →

Open to participants now

11 of the 17 studies in Histiocytosis, Langerhans-Cell with a site in China are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 19 Histiocytosis, Langerhans-Cell studies recruiting now, 8 (42%) set no upper age limit and 10 (53%) stop at 75 or younger; 13 take children under 18; 1 takes healthy volunteers.

This study: 0 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Histiocytosis, Langerhans-Cell with a site in China, or all of them as a file.
02

Study summary

Langerhans cell histiocytosis (LCH) is the most common histiocytic disorder in children, caused by excessive proliferation and accumulation of Langerhans cells (a type of immune cell) in various body tissues. The annual incidence is about 2.6-8.9 cases per million children.Clinical presentation varies widely.

Mild (low-risk) cases may resolve spontaneously or cause minimal issues with excellent outcomes. Severe multisystem LCH involves multiple organs, particularly high-risk sites such as liver, spleen, or bone marrow, leading to poorer prognosis and potential life-threatening complications without appropriate treatment.Standard first-line therapy for many children is prednisone (a corticosteroid) plus vinblastine (chemotherapy). Trials like LCH-III show near-100% survival in low-risk disease, but long-term survival drops to \~80% in high-risk cases. Reactivation occurs in \~37% of low-risk patients post-treatment, and \~50% of children eventually develop resistance, resulting in progression or relapse. Treatment failure heightens risks of long-term sequelae, including growth retardation, endocrine dysfunction, and neurological damage, severely impacting quality of life.

More than half of LCH cases harbor the BRAF V600E mutation, activating the MAPK pathway abnormally. This has driven development of targeted MAPK inhibitors (e.g., vemurafenib, dabrafenib, trametinib), which demonstrate strong efficacy and acceptable safety (mainly manageable skin rash) in relapsed/refractory pediatric cases, with no reported secondary malignancies to date. These agents provide rapid symptom relief and durable control, though monotherapy often fails to eradicate abnormal cells in multisystem disease, leading to relapse after discontinuation.

No MAPK inhibitors were previously approved specifically for LCH. In 2025, luvometinib (developed by Fosun Pharma, China; a selective MEK1/2 inhibitor) received approval in China for adult LCH and histiocytic neoplasms. Adult studies showed \~83% objective response rate and \~74% progression-free at ≥12 months, with mostly mild side effects (skin issues, hypertriglyceridemia) and no discontinuations due to serious toxicity.

Laboratory evidence indicates MAPK overactivation confers apoptosis resistance to LCH cells; combining MAPK inhibitors with chemotherapy may enhance cell killing and leverage chemotherapy-induced immune microenvironment changes for better clearance.

Small studies and real-world data in refractory LCH support this: combination regimens yielded low relapse rates (especially with prolonged therapy), 100% responses in some pediatric cohorts with sustained remission and no added severe toxicity, and notably lower relapse (20% vs 75% with inhibitor alone) in our center's early experience with LCH-III backbone plus MAPK inhibitor.

This multicenter randomized trial will enroll children with multisystem LCH, assigning them to modified standard LCH-III chemotherapy alone or the same regimen combined with luvometinib, to evaluate whether adding this targeted agent improves outcomes.

Read the detailed description

Lab studies show that when the MAPK pathway is overactive, it makes LCH cells harder to kill (more resistant to dying naturally). Combining an MAPK inhibitor with chemotherapy might make the abnormal cells easier to destroy. Chemotherapy also changes the immune environment in the body, which could help clear out the bad cells more completely.

Several small studies and real-world experiences have already tested this idea in children and adults with hard-to-treat LCH:

One study combined MAPK inhibitors with certain chemotherapy drugs and saw very few relapses, especially when treatment lasted longer.

Another study using a similar approach achieved 100% response in a group of children (including some as first treatment), with most staying in remission afterward, and no extra serious side effects from the combination.

A Chinese study using prednisone, another chemo drug, plus an MAPK inhibitor showed good results with low relapse after stopping.

Early data from our own center found that children who got an MAPK inhibitor together with the standard LCH-III treatment had much lower relapse rates (only 20%) compared to those who got the inhibitor alone (75% relapse).

Based on this growing evidence, this study plans to run a large, carefully designed trial at multiple hospitals. It will randomly assign children with multisystem LCH to receive either the improved (modified) version of the standard LCH-III chemotherapy alone, or the same chemotherapy combined with luvometinib. The goal is to compare how well each approach works and to learn more about whether adding this targeted drug to chemotherapy can improve treatment for children with this disease.

03

Conditions studied

  • Langerhans Cell Histiocytosis (LCH)

Keywords

  • Langerhans Cell Histiocytosis
  • Luvometinib
04

Who can participate

Ages eligible
0 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Children aged 0-18 years, of either sex.
  2. confirmed diagnosis of Langerhans cell histiocytosis (LCH) with positive staining for CD1a and/or CD207 (Langerin), and no prior treatment specifically directed against LCH.
  3. Multisystem involvement of LCH, as determined by clinical and imaging evaluation.
  4. Provision of written (by parent/legal guardian and, where appropriate, assent from the child), with willingness to comply with the study treatment regimen and follow-up assessments.

Exclusion criteria

Exclusion Criteria:

  1. Presence of any other significant underlying medical condition, including but not limited to primary immunodeficiency disorders, congestive heart failure, renal insufficiency, chronic viral hepatitis, infection, or status post solid organ transplantation.
  2. History of a second (secondary) .
  3. interval > 0.47 seconds on performed prior to enrollment.
  4. Ophthalmologic screening prior to enrollment revealing retinal vein occlusion, retinal pigment epithelial detachment, or other ocular abnormalities that, in the opinion of the investigator, contraindicate participation.
  5. LCH harboring Class 3 MEK pathway mutations, specifically the following alterations: L98_I103del, L98_K104del, P105_A106del, P105_I107delinsL, L101_I103delinsF, E102_I103delinsF, E102_I103del, E102_I103delinsV, E102_I103delinsVN, E102_K104delinsQ, or I103_A106del.
  6. Refusal or inability to provide written (or assent, as applicable).
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Modified LCH-III Chemotherapy + Luvometinib (Experimental Arm)

    Participants receive the same modified LCH-III chemotherapy regimen (prednisone, vinblastine, mercaptopurine) combined with oral luvometinib throughout the treatment period

    Drug: Prednisone · Drug: Vincristine · Drug: Mercaptopurine · Drug: Luvometinib

  • Active comparator
    Modified LCH-III Chemotherapy Alone (Control Arm)

    Participants receive the modified standard LCH-III chemotherapy regimen consisting of prednisone and vincristine.

    Drug: Prednisone · Drug: Vincristine · Drug: Mercaptopurine

Interventions

  • Corticosteroid administered orally as part of the modified LCH-III regimen

  • Intravenous vinca alkaloid chemotherapy agent used in the modified LCH-III regimen

  • Oral purine analog antimetabolite used in the maintenance phase of therapy for multisystem LCH

  • Oral selective MEK1/2 inhibitor added to the experimental arm. Administered daily in combination with modified LCH-III chemotherapy for multisystem Langerhans cell histiocytosis.

06

What researchers measure

Primary outcomes

  1. Event-Free survival rate

    Event-free survival (EFS) is defined as the time from Day 1 to the first occurrence of any event, including disease reactivation , second primary malignancy, or death from any cause. Events will be assessed by clinical examination, imaging, and laboratory tests. The 2-year EFS rate will be estimated using the Kaplan-Meier method, reported as percentage with 95% confidence interval.

    Time frame: From Day 1 until the date of first event or last follow-up, assessed up to 2 years.

Secondary outcomes

  1. Objective response rate

    Objective response rate (ORR) is defined as the proportion of participants achieving NAD or ADB at the specified time points. Responses will be assessed by clinical evaluation, imaging, and risk organ function (if involved). ORR will be reported separately at 1 month and 3 months as percentage of participants with NAD or ADB (combined), with exact 95% confidence intervals.

    Time frame: At 1 month and 3 months post-treatment

  2. Overall survival rate

    Overall survival (OS) is defined as Day 1 to death from any cause. Participants alive at last follow-up will be censored. The 2-year OS rate will be estimated using the Kaplan-Meier method and reported as percentage with 95% confidence interval.

    Time frame: From Day1 until date of death from any cause or last follow-up, assessed up to 2 years.

  3. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

    Safety and tolerability of the combination regimen (luvometinib added to modified LCH-III chemotherapy: prednisone + Vincristine backbone) will be assessed by the number of participants experiencing treatment-related adverse events (TRAEs), and serious adverse events (SAEs). Events will be graded according to NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Data will be summarized as: Incidence of any TRAE (percentage of participants) , Incidence by maximum grade (e.g., Grade 3-5) ,Incidence of specific events of interest (e.g., skin rash, hypertriglyceridemia, cytopenias) and Rate of treatment discontinuation due to toxicity

    Time frame: From Day 1 until through study completion, an average of 2 years

07

Study locations

11 of 11 sites recruiting
08

References and documents

Publications

  • Lei J, Wang W, Lin D, Zhu C, Jia W, Weng W, Liu X, Ma Y, Wang Z, Yang L, He X, He Y, Li Y. Vemurafenib combined with chemotherapy achieved sustained remission in pediatric LCH: a multi-center observational study. J Cancer Res Clin Oncol. 2024 Jan 17;150(1):12. doi: 10.1007/s00432-023-05551-y. PubMed 38231288 ↗
  • Evseev D, Osipova D, Kalinina I, Raykina E, Ignatova A, Lyudovskikh E, Baidildina D, Popov A, Zhogov V, Semchenkova A, Litvin E, Kotskaya N, Cherniak E, Voronin K, Burtsev E, Bronin G, Vlasova I, Purbueva B, Fink O, Pristanskova E, Dzhukaeva I, Erega E, Novichkova G, Maschan A, Maschan M. Vemurafenib combined with cladribine and cytarabine results in durable remission of pediatric BRAF V600E-positive LCH. Blood Adv. 2023 Sep 26;7(18):5246-5257. doi: 10.1182/bloodadvances.2022009067. PubMed 37216396 ↗
  • Karri V, Lin H, Velazquez J, Batajoo A, Parekh D, Stanton W, Abhyankar H, El-Mallawany NK, Agrusa J, Eckstein O, Gulati N, Schwartz J, Woods-Swafford W, Boyd J, Saha A, Allen CE, McClain KL. Clinical, radiological and molecular responses to combination chemotherapy with MAPK pathway inhibition in relapsed and refractory Langerhans cell histiocytosis. Br J Haematol. 2024 May;204(5):1882-1887. doi: 10.1111/bjh.19380. Epub 2024 Mar 19. PubMed 38501390 ↗
  • Bigenwald C, Le Berichel J, Wilk CM, Chakraborty R, Chen ST, Tabachnikova A, Mancusi R, Abhyankar H, Casanova-Acebes M, Laface I, Akturk G, Jobson J, Karoulia Z, Martin JC, Grout J, Rafiei A, Lin H, Manz MG, Baccarini A, Poulikakos PI, Brown BD, Gnjatic S, Lujambio A, McClain KL, Picarsic J, Allen CE, Merad M. BRAFV600E-induced senescence drives Langerhans cell histiocytosis pathophysiology. Nat Med. 2021 May;27(5):851-861. doi: 10.1038/s41591-021-01304-x. Epub 2021 May 6. PubMed 33958797 ↗
  • Hogstad B, Berres ML, Chakraborty R, Tang J, Bigenwald C, Serasinghe M, Lim KPH, Lin H, Man TK, Remark R, Baxter S, Kana V, Jordan S, Karoulia Z, Kwan WH, Leboeuf M, Brandt E, Salmon H, McClain K, Poulikakos P, Chipuk J, Mulder WJM, Allen CE, Merad M. RAF/MEK/extracellular signal-related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions. J Exp Med. 2018 Jan 2;215(1):319-336. doi: 10.1084/jem.20161881. Epub 2017 Dec 20. PubMed 29263218 ↗
  • Cao XX, Zhu Q, Cai Z, Ma J, Zhou H, Chang L, Zhong LP, Wu ZL, Wang X, Han P, Lin HM, Wei Z, Guo JY, Zheng Y, Li J. Luvometinib in patients with Langerhans cell histiocytosis, Erdheim-Chester disease, and other histiocytic neoplasms: a single-arm, multicentre, phase 2 study. EClinicalMedicine. 2025 Sep 17;88:103486. doi: 10.1016/j.eclinm.2025.103486. eCollection 2025 Oct. PubMed 41035796 ↗
  • Keam SJ. Luvometinib: First Approval. Drugs. 2025 Sep;85(9):1177-1183. doi: 10.1007/s40265-025-02217-6. Epub 2025 Aug 2. PubMed 40751881 ↗
  • Whitlock JA, Geoerger B, Dunkel IJ, Roughton M, Choi J, Osterloh L, Russo M, Hargrave D. Dabrafenib, alone or in combination with trametinib, in BRAF V600-mutated pediatric Langerhans cell histiocytosis. Blood Adv. 2023 Aug 8;7(15):3806-3815. doi: 10.1182/bloodadvances.2022008414. PubMed 36884302 ↗
  • Cournoyer E, Ferrell J, Sharp S, Ray A, Jordan M, Dandoy C, Grimley M, Roy S, Lorsbach R, Merrow AC, Nelson A, Bartlett A, Picarsic J, Kumar A. Dabrafenib and trametinib in Langerhans cell histiocytosis and other histiocytic disorders. Haematologica. 2024 Apr 1;109(4):1137-1148. doi: 10.3324/haematol.2023.283295. PubMed 37731389 ↗
  • Donadieu J, Larabi IA, Tardieu M, Visser J, Hutter C, Sieni E, Kabbara N, Barkaoui M, Miron J, Chalard F, Milne P, Haroche J, Cohen F, Helias-Rodzewicz Z, Simon N, Jehanne M, Kolenova A, Pagnier A, Aladjidi N, Schneider P, Plat G, Lutun A, Sonntagbauer A, Lehrnbecher T, Ferster A, Efremova V, Ahlmann M, Blanc L, Nicholson J, Lambilliote A, Boudiaf H, Lissat A, Svojgr K, Bernard F, Elitzur S, Golan M, Evseev D, Maschan M, Idbaih A, Slater O, Minkov M, Taly V, Collin M, Alvarez JC, Emile JF, Heritier S. Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study. J Clin Oncol. 2019 Nov 1;37(31):2857-2865. doi: 10.1200/JCO.19.00456. Epub 2019 Sep 12. PubMed 31513482 ↗
  • Haupt R, Nanduri V, Calevo MG, Bernstrand C, Braier JL, Broadbent V, Rey G, McClain KL, Janka-Schaub G, Egeler RM. Permanent consequences in Langerhans cell histiocytosis patients: a pilot study from the Histiocyte Society-Late Effects Study Group. Pediatr Blood Cancer. 2004 May;42(5):438-44. doi: 10.1002/pbc.20021. PubMed 15049016 ↗
  • Parekh D, Lin H, Batajoo A, Peckham-Gregory E, Karri V, Stanton W, Scull B, Fleishmann R, El-Mallawany N, Eckstein OS, Prudowsky ZD, Gulati N, Agrusa JE, Ahmed AZ, Chu R, Dietz MS, Goldman SC, Hogarty MD, Imran H, Intzes S, Kim JM, Kopp LM, Levy CF, Neff P, Pillai PM, Sisk BA, Schiff DE, Trobaugh-Lotrario AD, Walkovich K, McClain KL, Allen CE. Clofarabine monotherapy in aggressive, relapsed and refractory Langerhans cell histiocytosis. Br J Haematol. 2024 May;204(5):1888-1893. doi: 10.1111/bjh.19376. Epub 2024 Mar 19. PubMed 38501389 ↗
  • Lin H, Batajoo A, Peckham-Gregory E, Zinn D, Eckstein OS, El-Mallawany NK, Gulati N, Prudowsky ZD, Scull B, Velazquez J, Abhyankar H, Simko SJ, Vakula D, Fleischmann R, Karri V, Hicks MJ, Fisher KE, Curry CV, Roy A, Schiff D, Heym KM, Scheurer ME, Parsons DW, Merad M, Man TK, McClain KL, Picarsic J, Allen CE. BRAF V600E-positive mononuclear cells in blood at diagnosis portend treatment failure and neurodegeneration in pediatric LCH. Blood. 2025 Jul 10;146(2):206-218. doi: 10.1182/blood.2024026671. PubMed 40167581 ↗
  • Rodriguez-Galindo C, Allen CE. Langerhans cell histiocytosis. Blood. 2020 Apr 16;135(16):1319-1331. doi: 10.1182/blood.2019000934. PubMed 32106306 ↗

Individual participant data

Plan to share: No — IPD might be shared in the future upon approval by the ethics committee and under a data use agreement.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2026; primary completion for Dec 2030, 58 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2026
First posted
Feb 24, 2026
StartEst.
Feb 13, 2026
Primary completionEst.
Dec 31, 2030
CompletionEst.
Dec 31, 2030
Last update
Feb 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07431060
Lead sponsor
West China Second University Hospital
Responsible party
Xia Guo (Professor of Pediatrics, West China Second University Hospital) — Principal investigator
First posted
Feb 24, 2026
Start date
Feb 13, 2026 (estimated)
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Feb 24, 2026

Study contacts

Xue Tang
Contact
txily0912@126.com
86+18280145819

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Luvometinib

Start the discussion